Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial.
Blood
; 135(20): 1739-1749, 2020 05 14.
Article
in En
| MEDLINE
| ID: mdl-32160294
Full text:
1
Database:
MEDLINE
Main subject:
Pyrazoles
/
Hematopoietic Stem Cell Transplantation
/
Hematologic Neoplasms
/
Graft vs Host Disease
Type of study:
Clinical_trials
/
Etiology_studies
/
Prognostic_studies
Limits:
Adolescent
/
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Year:
2020
Type:
Article